000			02113 a2200565 4500
005			20250517045319.0
264		0	_c20160906
008			201609s 0 0 eng d
022			_a1538-8514
024	7		_a10.1158/1535-7163.MCT-14-1055-T _2doi
040			_aNLM _beng _cNLM
100	1		_aShang, Zhiqun
245	0	0	_aAntiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression. _h[electronic resource]
260			_bMolecular cancer therapeutics _cNov 2015
300			_a2586-94 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
650	0	4	_aAndrogen Antagonists _xadministration & dosage
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology
650	0	4	_aBCG Vaccine _xadministration & dosage
650	0	4	_aCell Line, Tumor
650	0	4	_aCell Movement _xdrug effects
650	0	4	_aCell Survival _xdrug effects
650	0	4	_aCurcumin _xadministration & dosage
650	0	4	_aDisease Progression
650	0	4	_aDrug Synergism
650	0	4	_aFemale
650	0	4	_aFlutamide _xadministration & dosage
650	0	4	_aGene Expression _xdrug effects
650	0	4	_aHumans
650	0	4	_aIntegrin alpha5beta1 _xgenetics
650	0	4	_aInterleukin-6 _xgenetics
650	0	4	_aMacrophages _xdrug effects
650	0	4	_aMice
650	0	4	_aReceptors, Androgen _xmetabolism
650	0	4	_aReverse Transcriptase Polymerase Chain Reaction
650	0	4	_aTreatment Outcome
650	0	4	_aUrinary Bladder Neoplasms _xdrug therapy
700	1		_aLi, Yanjun
700	1		_aZhang, Minghao
700	1		_aTian, Jing
700	1		_aHan, Ruifa
700	1		_aShyr, Chih-Rong
700	1		_aMessing, Edward
700	1		_aYeh, Shuyuan
700	1		_aNiu, Yuanjie
700	1		_aChang, Chawnshang
773	0		_tMolecular cancer therapeutics _gvol. 14 _gno. 11 _gp. 2586-94
856	4	0	_uhttps://doi.org/10.1158/1535-7163.MCT-14-1055-T _zAvailable from publisher's website
999			_c25160559 _d25160559